1. FDA Press Release. Statement from FDA Commissioner Scott Gottlieb M.D. and Peter Marks M.D. Ph.D. Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies; [accessed 2022 Jul 14]. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics
2. Institute for Clinical and Economic Review. 2020-2023 value assessment framework; [accessed 2022 Jul 27]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_013120-4.pdf
3. National Institute of Health and Care Excellence. The guidelines manual. Process and methods [PMG6]; 2012 [accessed 2022 Oct 16]. Available from: https://www.nice.org.uk/process/pmg6/chapter/assessing-cost-effectiveness
4. Neumann PJ Ollendorf DA. Why so few value assessments on health services and procedures and what should be done?; 2022 [accessed 2023 Feb 16]. Available from: https://www.healthaffairs.org/content/forefront/why-so-few-value-assessments-health-services-and-procedures-and-should-done
5. Institute for Clinical and Economic Review. Adapted value assessment methods for high-impact “single and short-term therapies” (SSTs); [accessed 2022 Jul 13]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_SST_FinalAdaptations_111219.pdf